2025-02-02 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Performance Review

**0. Summary Statistics:**

* **Ticker:** UNH
* **Company:** UnitedHealth Group Inc. is a diversified healthcare company providing a range of health benefits and services.
* **Cumulative Return (UNH):** 150.21%
* **Cumulative Return (VOO - S&P 500):** 119.91%
* **Return Difference (UNH vs VOO):** 30.3%
* **Relative Divergence (based on historical range):** 24.7% (This indicates UNH's performance is relatively strong compared to the S&P 500 historically,  but not exceptionally high considering the range.)


**1. Performance Comparison & Alpha/Beta Analysis:**

UNH has significantly outperformed the S&P 500 (VOO) over the observed period, showing a 30.3% higher cumulative return.  The relative divergence suggests this outperformance is considerable within the historical context of its performance relative to the S&P 500, but not at an extreme level.

The provided Alpha/Beta analysis reveals consistently positive alpha values across different periods, indicating UNH's outperformance relative to the market benchmark. The beta values are above 1, suggesting higher volatility than the overall market.  Noteworthy is the negative CAGR (-24%) and high MDD (-57%) in 2022-2024, highlighting significant risk during that specific period.  The substantial market capitalization (Cap(B)) shows UNH is a large-cap stock.


**2. Recent Price Movement:**

* **Closing Price:** $542.49
* **5-Day Moving Average:** $542.43
* **20-Day Moving Average:** $527.92
* **60-Day Moving Average:** $550.56

The price is slightly below the 5-day and 60-day moving averages, indicating a minor short-term downward trend,  but above the 20-day moving average suggesting some support.  The recent price decrease (-$0.56) is relatively small and doesn't signal a significant negative event.


**3. Technical Indicators & Expected Return:**

* **RSI:** 59.29 (Slightly above neutral; not overbought)
* **PPO:** 0.68 (Positive, suggesting bullish momentum)
* **Delta Relative Divergence (20-day):** +4.9 (Short-term upward trend)
* **Expected Return:** 239.0% (This is a very high projected long-term return and should be treated with significant caution. It's crucial to understand the assumptions and limitations of this projection.)


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue         |
|------------|--------|-----------------|
| 2024-11-04 | 6.56   | $100.82B       |
| 2024-08-09 | 4.58   | $98.86B        |
| 2024-05-09 | -1.53  | $99.80B        |
| 2023-11-06 | 6.31   | $92.36B        |
| 2024-11-04 | 6.31   | $92.36B        | *(Duplicate entry, likely a data error)*


Revenue shows consistent high numbers, however, EPS fluctuates significantly, with a notably negative value in Q2 2024.  The data inconsistency (duplicate entry) warrants further investigation for accuracy.


**5. Financial Information:**

**Revenue and Profitability:** Revenue remains relatively stable and high. Profit margins show some fluctuation but generally remain high and healthy, except for a slight decrease in recent quarters.

**Capital and Profitability:**  Equity has grown over time. ROE shows variability, with negative values in Q1 2024, indicating a period of lower profitability.


**6. Overall Analysis:**

UNH has demonstrated strong historical performance relative to the S&P 500, indicated by consistently positive alpha and high cumulative returns.  However,  recent performance shows some volatility and a significant downturn in 2022-2024. While technical indicators suggest a relatively positive short-term outlook (but not extremely bullish), the projected 239% expected return is exceptionally high and needs substantial scrutiny.  The earnings data show some inconsistency requiring clarification, while revenue remains strong but EPS exhibits volatility.  Careful consideration of the risks associated with UNH's high beta and the significant fluctuations in profitability are crucial before making any investment decisions.  The high expected return should be viewed skeptically without understanding the underlying assumptions and methodology.  Further research into the cause of the Q2 2024 negative EPS and the data duplication is recommended.
